Description
Impressive response to eribulin in endocrine- and chemotherapy-resistant metastatic breast cancer
Article: Impressive response to eribulin in endocrine- and chemotherapy-resistant metastatic breast cancer
€2.42
Related products
-
Article: Highlights in gynaecological cancers
€2.42 Add to cart -
Article: Clinically meaningful survival benefit with atezolizumab + nab-paclitaxel in previously untreated patients with PD-L1+ metastatic triple negative breast cancer
€2.42 Add to cart -
Article: Highlights in squamous cell carcinoma of the head and neck
€2.42 Add to cart -
1 year access Online Belgian Journal of Hematology (BJH)
€43.60 Add to cart
